The bioactive lipid lysophosphatidate (LPA) is produced mainly by the secreted enzyme autotaxin (ATX) ( 1-3 ). The ATX gene is among the 40 most upregulated genes in metastatic cancers ( 4 ). LPA signals through at least six G-proteincoupled receptors to increase cell division, survival, migration, and angiogenesis ( 1-3 ). Overexpression of ATX, LPA 1 , LPA 2 , or LPA 3 receptors in mammary cells causes spontaneous development of mammary tumors in mice ( 5 ). Women with breast carcinomas that express high levels of LPA 3 receptors in cancer epithelial cells, or ATX in stromal cells, have larger tumors, nodal involvement, and higher stage disease ( 6 ). LPA produces resistance to the cytotoxic effects of paclitaxel ( 2, 7-9 ), carboplatin ( 10 ), and radiation-induced cell death ( 2,11,12 ). Inhibiting ATX activity and lowering LPA concentrations in plasma and tumors decreases the initial phase of breast tumor growth and subsequent lung metastasis by ف 60% in a mouse model ( 13 ). These combined results provide strong evidence that increased LPA signaling in cancer cells promotes the growth and metastasis of breast tumors.The present studies focus on a different approach to attenuating LPA signaling. This involves increasing the expression of lipid phosphate phosphatase-1 (LPP1), which is a member of a family of three phosphatases that dephosphorylate bioactive lipid phosphates and pyrophosphates ( 14-16 ). Despite this broad specifi city for lipid phosphates that is observed with cell-free systems, changing the expression of the different LPPs in animal models produces different